ProPhase Labs Q2 FY26 net loss narrows to $3 million; revenue falls to $1 million - PRPH News | RalliesProPhase Labs Q2 FY26 net loss narrows to $3 million; revenue falls to $1 million
P
PRPH• Q2 FY26 results
- ProPhase Labs posted a GAAP net loss from continuing operations of $3 million, or $0.22 per share, for Q2 2026.
- Net revenue slipped to $1 million from $1.2 million a year earlier, on lower supplements sales; no diagnostic-services revenue.
- Gross margin narrowed to 22.4% from 58.9% in the year-ago quarter, reflecting consumer-products margin variability and product mix.
- General and administration expense fell to $2.9 million from $4.6 million, driven by lower personnel, overhead, and professional fees.
- Non-GAAP adjusted EBITDA from continuing operations improved to a loss of $561,000 from a loss of $807,000.
•
